SUPN: SEC Form 8-K filed by Supernus Pharmaceuticals Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for SUPN
Across the 20 sessions after earlier SUPN headlines, the stock closed higher 13 times and lower 5 times, with a median move of 1.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SUPN | SPY |
|---|---|---|---|
| Oct 22, 2026 | Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) | +2.1% | -1.2% |
| Oct 19, 2026 | Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 | +5.2% | +0.4% |
| Sep 3, 2026 | Supernus Pharmaceuticals to Participate in September Investor Conferences | -0.1% | +1.0% |
| Aug 31, 2026 | Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD | +1.1% | -0.3% |
| Aug 3, 2026 | Supernus Announces Second Quarter 2026 Financial Results | +3.1% | +1.4% |
| Jul 23, 2026 | Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 | +0.5% | -1.2% |
Quantisnow market dataNASDAQ
SUPN
Supernus Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2012
Get push alerts for SUPN
Full SUPN profile on Quantisnow Follow SUPN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time